Literature DB >> 12372888

Microstaging of pT1 transitional cell carcinoma of the bladder. Does it really differentiate two populations with different prognoses? (pT1 subcategory).

Sinan Sözen1, Cem Akbal, Cenk Sökmensüer, Sinan Ekici, Haluk Ozen.   

Abstract

INTRODUCTION: Our objective was to evaluate the feasibility and value of microstaging in pT1 transitional cell carcinoma (TCC) of the bladder in a well-defined group of patients treated with transurethral resection (TUR) only.
MATERIALS AND METHODS: The clinical records of 152 patients who underwent TUR for the treatment of primary superficial TCC of the bladder between 1983 and 1997 were reviewed. Patients with primary carcinoma in situ and who received adjuvant intravesical treatments were excluded from study. We subclassified the pT1 tumors into two groups according to muscularis mucosae (MM) invasion (pT1 and pT1b). The recurrence and progression rate of cancers was analyzed according to the stage, grade, multiplicity and tumor size. Mean follow-up was 68 months. Estimation of the cumulative distribution of the disease-free interval in separate groups was calculated according to the Kaplan-Meier method. Multivariate analysis of the data was performed by using Cox regression method. A value of p < 0.05 was taken to be statistically significant with odds ratios.
RESULTS: Of the 152 patients, tumor stage was pTa in 62 (40.8%) patients and pT1 in 90 (59.2%) patients. Among those pT1 tumors, MM was identified in 50 (55.5%) of cases (pT1a = 34, pT1b = 16). In the remaining 40 (44.5%) patients, MM could not be assessed. Kaplan-Meier analysis revealed that recurrence and progression were statistically significant for stage, multiplicity and grade of tumor. However, multivariate analysis revealed that stage was the only prognostic factor for recurrence and progression (p = 0.0001).
CONCLUSION: The present study underscores the fact that pT1b tumors have a distinct natural history. If initial conservative treatment is selected, the patients must be followed very cautiously. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2002        PMID: 12372888     DOI: 10.1159/000063941

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  4 in total

1.  Consistency of microstaging pT1 bladder transitional cell carcinoma.

Authors:  Lorna Cottrell; Edwin Robert Nairn; Mario Hair
Journal:  J Clin Pathol       Date:  2007-02-23       Impact factor: 3.411

2.  The relationship between the expression of E-cadherin and tumor recurrence and progression in high-grade stage T1 bladder urothelial carcinoma.

Authors:  Fikret Erdemir; Faruk Ozcan; Isin Kilicaslan; Bekir S Parlaktas; Nihat Uluocak; Ozgur Gokce
Journal:  Int Urol Nephrol       Date:  2007-03-06       Impact factor: 2.370

3.  Prognostic Significance of Substaging according to the Depth of Lamina Propria Invasion in Primary T1 Transitional Cell Carcinoma of the Bladder.

Authors:  Ji Yong Lee; Hee Jae Joo; Dae Sung Cho; Sun Il Kim; Hyun Soo Ahn; Se Joong Kim
Journal:  Korean J Urol       Date:  2012-05-18

4.  Prognostic value of T1 substaging on oncological outcomes in patients with non-muscle-invasive bladder urothelial carcinoma: a systematic literature review and meta-analysis.

Authors:  Mehdi Kardoust Parizi; Dmitry Enikeev; Petr V Glybochko; Veronika Seebacher; Florian Janisch; Harun Fajkovic; Piotr L Chłosta; Shahrokh F Shariat
Journal:  World J Urol       Date:  2019-09-06       Impact factor: 4.226

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.